Detail for isoniazid
Basic Information
DrugID 57
DrugName isoniazid
DrugDetail Isoniazid (Laniazid, Nydrazid), also known as isonicotinylhydrazine (INH), is an organic compound that is the first-line anti tuberculosis medication in prevention and treatment. It was first discovered in 1912, and later in 1951 it was found to be effective against tuberculosis by inhibiting its mycolic acid (wax coat). Isoniazid is never used on its own to treat active tuberculosis because resistance quickly develops. Isoniazid also has an antidepressant effect, and it was one of the first antidepressants discovered. Isoniazid can also be used in the treatment of a BCG-oma. The compound was first synthesised in the early 20th century,but its activity against tuberculosis was first reported in the early 1950s and three pharmaceutical companies attempted unsuccessfully to simultaneously patent the drug (the most prominent one being Roche, who launched their version, Rimifon, in 1952). With the introduction of isoniazid, a cure for tuberculosis was first considered reasonable. Isoniazid is available in tablet, syrup, and injectable forms (given intramuscularly or intravenously). Isoniazid is available worldwide, is inexpensive and is generally well tolerated. It is manufactured from isonicotinic acid, which is produced from 4-methylpyridine.

http://en.wikipedia.org/wiki/Isoniazid

Indication For the treatment of all forms of tuberculosis in which organisms are susceptible.

http://www.drugbank.ca/drugs/DB00951

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
Amphotericin B Cordeiro Rde A, Brilhante RS, Rocha MF, Medrano DJ, Monteiro AJ, Tavares JL, de Lima RA, de Camargo ZP, Sidrim JJ. (2009) In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii. Int J Antimicrob Agents. 34(3):278-80.
Itraconazole Cordeiro Rde A, Brilhante RS, Rocha MF, Medrano DJ, Monteiro AJ, Tavares JL, de Lima RA, de Camargo ZP, Sidrim JJ. (2009) In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii. Int J Antimicrob Agents. 34(3):278-80.
Target
TargetName References EssentialGene? Link
(R)-limonene 6-monooxygenase No
(S)-3-amino-2-methylpropionate transaminase No
4-nitrophenol 2-hydroxylase No
Albendazole monooxygenase No
Arylamine N-acetyltransferase No
Catalase-peroxidase No
CYP1A1 No
CYPIA2 Yes
CYPIIC8 No
CYPIID6 No
Cytochrome P450 2A6 No
Cytochrome P450 2D6 No
Enoyl-[acyl-carrier-protein] reductase [NADH] Yes
Enoyl-[acyl-carrier-protein] reductase [NADH] 1 No
Enoyl-[acyl-carrier-protein] reductase [NADH] 2 No
Fatty acid synthase Yes
Glutathione transferase No
Protein-lysine 6-oxidase Yes
Peroxidase/catalase T No
monoamine oxidase (MAO) inhibitor No
mycolic acid synthesis inhibitor (enoyl-ACP reductse inhibitor) No
PathWay
PathWay Name Path Picture
pathway1
pathway2
pathway3
pathway4
pathway5
pathway6
pathway7